Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis

Completed · Phase 2

Conditions studied: Respiratory Tract Diseases, Lung Diseases, Lung Diseases, Interstitial, Pulmonary Fibrosis

In brief

The purpose of this study is to determine the possible efficacy of low dose, orally administered interferon alpha in subjects with Idiopathic Pulmonary Fibrosis (IPF).

Key facts

Study ID

NCT01442779

Run by

Texas Tech University Health Sciences Center

People needed

18

Starts

2000-09-01

Expected to finish

2007-05-01

Last updated by the study team

2012-04-20

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The only subjects to be included in this study are those diagnosed with Idiopathic Pulmonary Fibrosis with diagnosis based on the criteria published by the American Thoracic Society in the International Consensus Statement.
• Exclusion of other known causes of interstitial lung disease.
• Abnormal pulmonary function studies.
• Bibasilar reticular abnormalities with minimal ground glass opacities on HRCT scan.
• Biopsy or lavage showing no features supporting alternative diagnosis.
• Patient older than 50 years of age.
• Insidious onset of otherwise unexplained dyspnea on exertion.
• Duration greater than 3 months.
• Bibasilar, inspiratory crackles.

You may not qualify if…

• under the age of 50
• history of hypersensitivity to interferons
• history of hypersensitivity to biological products such as vaccines
• pregnant or lactating women
• women of child bearing age not pregnancy protected during the study
• unresolved serious cardiovascular disease

Where it is running

• Texas Tech University Health Sciences Center — Lubbock, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.